- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 49
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
- Interventions
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine, Azithromycin
- Drug
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Murray, Utah • Salt Lake City, Utah
- Conditions
- Individuals Undergoing Cardiac and General Surgery
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- COVID-19, SARS-CoV 2
- Interventions
- Hydroxychloroquine (HCQ), Azithromycin (Azithro), Placebo for Hydroxychloroquine, Placebo for Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 7 more
- Conditions
- Coronavirus, Acute Respiratory Infection, SARS-CoV Infection
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
- Interventions
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 28 Days and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Hydroxychloroquine (HC)
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Antiphospholipid Syndrome
- Interventions
- Hydroxychloroquine
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatocellular Cancer
- Interventions
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Solid Tumor, Advanced Breast Cancer
- Interventions
- Abemaciclib, Hydroxychloroquine 200 mg, Faslodex, Anastrazole, Letrozole, Hydroxychloroquine 400 mg, Hydroxychloroquine 600 mg
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
- Interventions
- Binimetinib Pill, Hydroxychloroquine Pill
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- WellStar Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Marietta, Georgia
- Conditions
- Diabetes Mellitus Type 2 With Hyperglycemia
- Interventions
- Hydroxychloroquine, Pioglitazone
- Drug
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer Recurrent
- Interventions
- Hydroxychloroquine Sulfate 200Mg Tab
- Drug
- Lead sponsor
- Patrick Hensley
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- COVID-19
- Interventions
- Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
- Drug
- Lead sponsor
- Ravi Amaravadi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Refractory or Relapsed Solid Tumors
- Interventions
- Sorafenib combined with Hydroxychloroquine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Retinitis Pigmentosa
- Interventions
- Hydroxychloroquine lower dose, Hydroxychloroquine higher dose
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Colorectal Cancer
- Interventions
- Vorinostat, Hydroxychloroquine, Regorafenib
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Hydroxychloroquine, Placebo Oral Capsule
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 15 Years to 49 Years
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Great Neck, New York + 4 more
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV, 2019 Novel Coronavirus
- Interventions
- Hydroxychloroquine, Vitamin C
- Drug · Dietary Supplement
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
- Interventions
- Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Placebo oral tablet, Monitoring Visit - Baseline, Monitoring Visit - Week 4, Monitoring Visit - Week 8, Weekly Assessment
- Drug · Other · Diagnostic Test
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 624 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Pre-diabetes
- Interventions
- hydroxychloroquine, Placebo
- Drug · Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- COVID-19, Corona Virus Infection, ARDS, Acute Respiratory Distress Syndrome
- Interventions
- Hydroxychloroquine, Placebo
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota